Every Form 4 that Oncolytics Biotech, Inc. (ONCY) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ONCY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ONCY filings page.
ONCOLYTICS BIOTECH INC director Wayne Pisano received a grant of stock options for 30,000 common shares. The options were granted at an exercise price of $1.06 per share, which equals the closing price of the company’s common stock on June 1, 2026.
The options vest in three equal annual installments, with the first tranche vesting on June 1, 2027, as long as Pisano continues in service or employment on each vesting date. After this grant, he holds 30,000 stock options directly under this award.
ONCOLYTICS BIOTECH INC director Jonathan Rigby received a new stock option grant covering 30,000 common shares. The options have an exercise price of $1.06 per share, equal to the June 1, 2026 closing price on the Nasdaq Capital Market, and expire on June 1, 2036.
The grant vests in three equal annual installments, with the first tranche vesting on June 1, 2027, contingent on his continued service or employment on each vesting date. Following this award, Rigby holds stock options for 30,000 shares directly.
Oncolytics Biotech Inc. reported that director Angela Holtham received a grant of stock options covering 30,000 common shares. The options have an exercise price of $1.06 per share, equal to the Nasdaq Capital Market closing price on June 1, 2026, and expire on June 1, 2036.
The grant vests in three equal annual installments, with the first tranche vesting on June 1, 2027, conditioned on her continued service or employment on each vesting date. This is a compensation-related award rather than an open-market share purchase or sale.
ONCOLYTICS BIOTECH INC director James T. Parsons received a grant of stock options for 30,000 common shares. The options have an exercise price of $1.06 per share, equal to the Nasdaq Capital Market closing price on June 1, 2026.
The award was granted at no cost to Parsons and vests in three equal annual installments starting on June 1, 2027, contingent on his continued service or employment. Following this grant, he holds options for 30,000 underlying common shares directly.
ONCOLYTICS BIOTECH INC Chief Financial Officer Kirk Look received a grant of stock options covering 260,000 common shares as compensation. The options have an exercise price of $1.06 per share, equal to the closing price on June 1, 2026, and expire on June 1, 2036.
The award vests in three equal annual installments, with the first tranche vesting on June 1, 2027, contingent on his continued service or employment on each vesting date. This filing reflects a routine equity incentive grant, with no open-market share purchases or sales reported.
ONCOLYTICS BIOTECH INC Chief Business Officer Andrew Aromando received a grant of 260,000 stock options. These options have an exercise price of $1.06 per share, equal to the closing price of the company’s common stock on the Nasdaq Capital Market on June 1, 2026.
The options cover 260,000 underlying common shares and expire on June 1, 2036. They vest in three equal annual installments, with the first tranche vesting on June 1, 2027, subject to his continued service or employment on each vesting date.
ONCOLYTICS BIOTECH INC reported a Form 4 for Chief Executive Officer Jared Kelly showing a compensation-related grant of stock options. He received options for 755,000 common shares at an exercise price of $1.06 per share, equal to the Nasdaq closing price on June 1, 2026.
The options expire on June 1, 2036 and vest in three equal annual installments starting on June 1, 2027, contingent on continued service. Following this award, his reported stock option holdings from this grant total 755,000 options.
ONCOLYTICS BIOTECH INC director Patricia S. Andrews received a grant of stock options covering 30,000 common shares. The options have an exercise price of $1.06 per share, equal to the closing price on the Nasdaq Capital Market on June 1, 2026, and expire on June 1, 2036.
The award vests in three equal annual installments, with the first tranche vesting on June 1, 2027, as long as she continues in service or employment on each vesting date. Following this grant, she holds 30,000 stock options directly.
ONCOLYTICS BIOTECH INC director Bernd R. Seizinger received a grant of stock options covering 30,000 common shares. The options have an exercise price of $1.06 per share, matching the closing price on the Nasdaq Capital Market on June 1, 2026, and expire on June 1, 2036.
The award vests in three equal annual installments starting on June 1, 2027, contingent on his continued service or employment on each vesting date. Following this grant, he holds stock options on 30,000 shares directly.
ONCOLYTICS BIOTECH INC reported that Chief Technology Officer Allison Hagerman received a grant of stock options covering 260,000 Common Shares. The options have an exercise price of $1.06 per share, matching the Nasdaq Capital Market closing price on June 1, 2026, and expire on June 1, 2036.
The award vests in three equal annual installments, with the first tranche vesting on June 1, 2027, conditioned on continued service or employment. Following this grant, Hagerman holds 260,000 stock options directly, and the filing does not show any share purchases or sales.
ONCOLYTICS BIOTECH INC director Deborah Margaret Brown received a stock option grant for 30,000 common shares. The option has an exercise price of $1.06 per share, matching the Nasdaq Capital Market closing price on June 1, 2026, and expires on June 1, 2036.
The award vests in three equal annual installments starting on June 1, 2027, conditioned on her continued service or employment on each vesting date. Following this grant, she holds options for 30,000 underlying common shares as reported in this filing.
ONCOLYTICS BIOTECH INC reported that Chief Medical Officer Thomas Charles Heineman received a grant of stock options as part of his compensation. The award covers 260,000 stock options for common shares at an exercise price of $1.06 per share, matching the closing price on June 1, 2026. These options expire on June 1, 2036 and vest in three equal annual installments starting on June 1, 2027, conditional on his continued service or employment on each vesting date. After this grant, he holds 260,000 stock options directly.
Oncolytics Biotech Inc. reported that Chief Operating Officer John Bearden McAdory received a grant of stock options as part of his compensation. He was awarded options covering 145,000 common shares at an exercise price of $1.06 per share, equal to the Nasdaq Capital Market closing price on June 1, 2026.
The options vest in three equal annual installments, with the first tranche vesting on June 1, 2027, as long as he continues in service or employment on each vesting date. The options expire on June 1, 2036. This is a derivative award, not an open-market stock purchase or sale.
ONCOLYTICS BIOTECH INC director Stephen C. Glover received a grant of 96,000 stock options. The options have an exercise price of $1.06 per share, equal to the Nasdaq closing price on June 1, 2026, and expire on June 1, 2036.
The options vest in three equal annual installments starting on June 1, 2027, contingent on Mr. Glover’s continued service or employment. This is a compensation-related award rather than an open-market purchase or sale of common shares.
Oncolytics Biotech Inc. director James T. Parsons reported an open-market purchase of 10,000 common shares of the company. The transaction took place at a price of $1.03 per share, indicating a direct cash investment in the stock. Following this trade, Parsons directly owns 41,849 common shares of Oncolytics Biotech Inc., reflecting an increased personal stake in the company’s equity.
Oncolytics Biotech Inc. chief executive officer Jared Kelly reported an open-market purchase of 5,050 common shares on March 12, 2026 at an average price of $0.96 per share. Following this transaction, he directly owns 114,050 common shares, indicating a modest increase in his personal stake.
Oncolytics Biotech Inc. CEO and director Kelly Jared reported buying additional common shares in the open market. On February 11, 2026, he purchased 5,600 common shares at a weighted average price of $0.836, and on February 12, 2026, he bought 29,500 common shares at a weighted average price of $0.842.
The filing notes these were executed through multiple trades at prices ranging from $0.820 to $0.856. After these transactions, Jared directly owns 109,000 Oncolytics Biotech common shares.
Oncolytics Biotech Inc. filed a Form 4 showing that its Chief Financial Officer, Kirk Look, made an open-market purchase of company stock. On February 12, 2026, he bought 12,000 common shares at a price of $0.842 per share. After this transaction, he directly beneficially owned 287,515 common shares of Oncolytics Biotech. The filing classifies this as a direct ownership position, reflecting additional personal investment by the company’s senior financial officer.
Oncolytics Biotech Inc. director Wayne Pisano reported an open-market purchase of 30,000 common shares of ONCY on February 12, 2026. The shares were bought at a weighted average price of $0.8446 per share, in multiple trades ranging from $0.83 to $0.85.
Following this transaction, Pisano directly holds 492,414 common shares of Oncolytics Biotech Inc. The filing notes that detailed trade-by-trade pricing information is available upon request for investors or regulators who want to review each individual purchase within the reported price range.
Oncolytics Biotech Inc. Chief Medical Officer Thomas Charles Heineman reported an open-market purchase of 12,132 common shares on February 12, 2026 at a price of $0.827 per share. Following this transaction, he directly owns 282,818 Oncolytics Biotech common shares.
Oncolytics Biotech Inc. director Deborah Margaret Brown bought additional company shares. On February 12, 2026, she made an open-market purchase of 25,000 common shares at a weighted average price of $0.8496 per share. After this transaction, she directly owns 109,851 common shares of Oncolytics Biotech Inc.
The filing notes that the purchase price reflects multiple trades executed within a range from $0.835 to $0.85 per share, and detailed trade breakdowns are available upon request.
Oncolytics Biotech Inc. VP of Product Development Allison Hagerman bought 10,000 common shares in the open market on February 12, 2026 at $0.8298 per share. After this purchase, she directly owned a total of 115,059 common shares of the company.
Oncolytics Biotech director Bernd R. Seizinger bought additional common shares in two open-market transactions. On February 11, 2026, he purchased 60,000 common shares at $0.8265 per share. On February 12, 2026, he bought another 40,000 common shares at $0.8466 per share.
After these transactions, Seizinger directly owns 566,991 common shares of Oncolytics Biotech Inc. The filing classifies both trades under transaction code "P," indicating purchases in the open market or private transactions.
Oncolytics Biotech Inc.'s Chief Business Officer, Andrew Aromando, bought additional company stock in the open market. On February 11, 2026, he purchased 29,600 common shares of Oncolytics Biotech at a weighted average price of $0.8587 per share, increasing his direct holdings to 55,100 common shares.
Oncolytics Biotech Inc. director Patricia S. Andrews bought 35,400 common shares in open-market transactions on February 12, 2026 at a weighted average price of $0.8557 per share. Following these purchases, she directly owns 78,128 common shares of the company.
The filing notes the trades were executed in multiple lots at prices ranging from $0.8483 to $0.86 per share, with the weighted average reported. Andrews has indicated she can provide full trade-by-trade pricing details to the company, its shareholders, or the SEC staff upon request.
Oncolytics Biotech Inc. director Bernd R. Seizinger reported buying additional common shares of the company. On January 16, 2026, he acquired 100,000 common shares of Oncolytics Biotech at a weighted average price of $1.0377 per share, through multiple trades executed between $1.0294 and $1.0499.
Following this purchase, Seizinger beneficially owns 466,991 common shares, held directly. The filing notes that full detail on the number of shares bought at each individual price within the stated range is available upon request from the company, any security holder, or the SEC staff.